TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder and CEO of Satellos, will present at the following investor conferences:
Stifel 2024 Virtual CNS Days
Format: Fireside Chat
Date: Wednesday, March 20 at 8:00 a.m. ET
Cantor Virtual Muscular Dystrophy Symposium
Format: Fireside Chat
Date: Wednesday, April 3 at 11:30 a.m. ET
The fireside chats will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the presentation.
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ontario. For more information, visit www.satellos.com.
